Medical AR Claims Management for Infectious Disease Practices

Medical AR claims management can include charge entry, coding review, claim scrubbing, submission, rejection clearing, denial categorization, appeals, payment reconciliation, underpayment review, and aging A/R follow-up. For infectious disease practices, the work may also address E/M, infusion, drug, hospital consult, OPAT, authorization, and medical-versus-pharmacy benefit workflows.

Infectious disease practices may combine cognitive visits with infusion, OPAT, buy-and-bill, specialty-drug, hospital consult, and contracted service workflows. Each can involve different documentation, coding, authorization, coverage, and reimbursement considerations. A useful claims process examines how those service lines connect from referral and eligibility through charge capture, payment, denial resolution, and account follow-up.

Yes. The available guidance addresses drug and administration claims, infusion billing, eligibility and authorization, medical-versus-pharmacy benefit questions, unit or NDC mismatches, payment reconciliation, underpayments, and aging high-dollar claims. Practices can use these areas to understand where an infusion claim may be delayed, denied, paid incorrectly, or left unresolved.

Revenue leakage can be investigated by reviewing reporting across payer, service line, and provider, then examining denial patterns, payment trends, A/R health, documentation, charge capture, and contract terms. This approach helps connect missing or delayed revenue to its source rather than treating every unpaid claim as the same problem.

Denial management resources address common root causes such as drug and administration coding, missing authorization, medical-versus-pharmacy benefit confusion, and under-documented consults. The process includes categorizing denial patterns and developing payer-specific appeals supported by clinical documentation, while returning findings to clinical, coding, and front-office teams to reduce recurrence.

Payment reconciliation compares reimbursement with expected payment for drug, administration, and E/M claims. A review can flag short-pays, incorrect fee schedule application, and unit or NDC mismatches. The findings can then support disputes and recovery tracking, while helping the practice understand whether contract or billing issues are affecting its balance sheet.

The resources are designed for infectious disease physicians, independent infectious disease practices, infectious disease group leaders, and medical practice administrators. They are relevant to practices evaluating revenue streams, launching or managing infusion and OPAT services, adding providers, reviewing operational decisions, or investigating why collections do not match the work being performed.

No. GrowInfectiousDisease states that it does not publish invented rates, benchmarks, drug acquisition costs, payment rates, or margin figures. Its tools and guidance are intended to help practices apply their own numbers and distinguish verified information from unknown or practice-specific figures when evaluating revenue-cycle and operational decisions.